Your Curated Oncology News

U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy


View Mobile version

contact us | advertise | OBRoncology.com |
Edit Profile | Mar 06, 2021

OBR Daily Logo

 

Featured Oncology News Headlines

U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy

(Gilead) Mar 5, 2021 - Kite, a Gilead Company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

read corporate press release Share on Facebook Share on Twitter Share on LinkedIn

 

Featured Editorial Board Comments

forumImage

U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer
H. Jack West, MD (Posted: March 05, 2021) - "Lorlatinib is an excellent ALK inhibitor, but beating crizotinib as first line therapy for patients with ALK-positive advanced NSCLC only puts it on par with alectinib as a current standard of care or..."

Read More >

 

 

Oncology Clinical News Headlines

 

Childhood Cancer Survivors, Providers Satisfied with Video Visits for Long-term Follow-up

(Dana-Farber) Mar 4, 2021 - When the COVID-19 pandemic limited in-person medical checkups last year, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, for the first time, offered video visits for long-term follow-up appointments for childhood cancer survivors.

read press release Share on Facebook Share on Twitter Share on LinkedIn

 

Earlier Colonoscopies Halve Subsequent Cancer Risk

(Scope Blog/Stanford Medicine) Mar 4, 2021 - Researchers have the real-world data from nearly 3 million people to show that initiating colonoscopy screening between the ages of 45 and 49 halves the risk of subsequent development of colorectal cancers. They published their findings recently in Gastroenterology.

read article Share on Facebook Share on Twitter Share on LinkedIn

 

Collagen Plays Protective Role During Pancreatic Cancer Development

(MD Anderson) Mar 4, 2021 - Contrary to long-held beliefs, Type I collagen produced by cancer-associated fibroblasts may not promote cancer development but instead plays a protective role in controlling pancreatic cancer progression, reports a new study from researchers at The University of Texas MD Anderson Cancer Center.

read press release Share on Facebook Share on Twitter Share on LinkedIn

 

Engineered 'Off the Shelf' Stem Cells Target Breast Cancer that Metastasizes to the Brain

(BWH) Mar 3, 2021 - Approximately 15-to-30 percent of patients with metastatic breast cancer have brain metastasis (BM), with basal-like breast cancer (BLBC) metastasizing to the brain most frequently.

read article Share on Facebook Share on Twitter Share on LinkedIn

 

Original Error

(Harvard Medical School) Mar 4, 2021 - There is no stronger risk factor for cancer than age. At the time of diagnosis, the median age of patients across all cancers is 66.

read article Share on Facebook Share on Twitter Share on LinkedIn

 

Immutep Expands Part B of TACTI-002 Study

(Yahoo! Finance) Mar 5, 2021 - Immutep Limited a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has decided to expand Part B of its TACTI-002 Phase II trial, under the study’s Simon’s two- stage clinical trial design.

read article Share on Facebook Share on Twitter Share on LinkedIn

 

Featured OBR Green Articles

Oncology Clinician Burnout: Causes, Cures and a Roadmap

Burnout among oncology clinicians has been exacerbated by increased stressors from the pandemic. We look at the causes and effects of this pervasive problem, and find out how ASCO is stepping up to alleviate practice burnout among cancer providers.
read article »   Facebook Twitter LinkedIn

 

 

Oncology Business & Policy News Headlines

ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics

(Markets Insider) Mar 4, 2021 - ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced a collaboration to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics.

read article Share on Facebook Share on Twitter Share on LinkedIn

 

Eligible Clinicians Will Not Face Payment Penalties for MIPS Performance in 2020

(ASCO in Action) Mar 2, 2021 - The Centers for Medicare & Medicaid Services (CMS) announced it will hold physicians harmless from Merit-based Incentive Payment System (MIPS) penalties due to the significant disruptions the COVID-19 public health emergency placed on physician practices’ performance in 2020.

read article Share on Facebook Share on Twitter Share on LinkedIn

 

Legislation Aims to Increase HPV Vaccine Awareness, Access, and Research

(ASCO in Action) Mar 4, 2021 - The Association for Clinical Oncology (ASCO) endorsed the “PREVENT HPV Cancers Act” (H.R. 1550), which was recently introduced by Representative Kathy Castor (FL-14).

read article Share on Facebook Share on Twitter Share on LinkedIn

 

New WHO/IAEA Publication Provides Guidance On Radiotherapy Equipment To Fight Cancer

(WHO) Mar 5, 2021 - More than 50% of cancer patients require radiotherapy as part of cancer care and it is frequently used to treat the most common types, such as breast, cervical, colorectal, and lung cancer. Yet, access to radiotherapy is inadequate, particularly in low- and middle-income countries.

read press release Share on Facebook Share on Twitter Share on LinkedIn

 

Memorial Sloan Kettering Expert Leads International Effort on Improving Global Health by Expanding Access to Radiology, Nuclear Medicine

(MSK) Mar 4, 2021 - An international Commission of nuclear medicine and medical imaging experts led by Dr. Hedvig Hricak, Chair of Memorial Sloan Kettering’s Department of Radiology, recently released data from the first ever report that quantified imaging and nuclear medicine resources worldwide.

read press release Share on Facebook Share on Twitter Share on LinkedIn

 

Marlboro Maker Altria Asks FDA To Spread The Word That Nicotine Doesn’t Cause Cancer

(CNBC) Mar 4, 2021 - Marlboro parent Altria is asking the Food and Drug Administration to help it spread the word that nicotine doesn’t cause cancer.

read article Share on Facebook Share on Twitter Share on LinkedIn

 

Memorial Cancer Institute/FAU Designated ‘Cancer Center Of Excellence’

(FAU) Mar 3, 2021 - A research partnership formed just last year by Memorial Healthcare System and Florida Atlantic University is already being recognized for quality care, results, and advances in research, and that’s great news for patients fighting cancer in South Florida.

read article Share on Facebook Share on Twitter Share on LinkedIn

 

 

OBR Resources

News Story Commentary

U.S. FDA Expands Approval of Pfizer’s LORBRENA...

Lorlatinib is an excellent ALK inhibitor, but beating crizotinib as first line therapy for patients...

H. Jack West, MD

2021-03-05


Cancer Patients Often Can’t Get Full Care With...

This article is biased from the perspective of hospital-based cancer care. Independent community on...

Ted Okon

2021-03-02


View All Commentary

OBR Green

ad


Read the latest issue here

Visit the OBR green archives

Upcoming Oncology Events

Advances in the Treatment of Colorectal Cancer (CancerCare Connect Education Workshop)

[by phone or online as a webcast]

March 8, 2021

more info


Managing Eye and Vision Changes Related to Cancer Treatments (CancerCare Connect Education Workshop)

[by phone or online as a webcast]

March 15, 2021

more info


17th St. Gallen International Breast Cancer Conference 2021

Vienna, Austria

March 17 - 20, 2021

more info


View ALL Events

 

 

Broader Healthcare & Pharma News Headlines

 

Most Coronavirus Deaths Have Occurred In Countries Where Majority Of Adults Are Overweight

(Washington Post) Mar 4, 2021 - The vast majority of global coronavirus deaths occurred in nations with high levels of obesity, according to a report linking overweight populations with more severe coronavirus-related illness and mortality.

read article (free registration required) Share on Facebook Share on Twitter Share on LinkedIn

 

What To Look For In Lilly’s Eagerly Awaited Alzheimer’s Data

(STAT Plus) Mar 5, 2021 - Earlier this year, amid the increasingly bruising debate over Biogen’s controversial treatment for Alzheimer’s disease, Eli Lilly issued a six-paragraph press release extolling the promise of an under-the-radar therapy of its own — one that, if effective, would seem to support Biogen’s claims as well.

read article (paid subscription required) Share on Facebook Share on Twitter Share on LinkedIn

 

Requests for Brand Name Over Generic Prescription Drugs Cost the Medicare Program an Additional $1.7 Billion in a Single Year, Study Finds

(JHBSPH) Mar 2, 2021 - The Medicare Part D program would have saved $977 million in a single year if all branded prescription drugs requested by prescribing clinicians had been substituted by a generic option, according to a new study by researchers at the Johns Hopkins Bloomberg School of Public Health.

read press release Share on Facebook Share on Twitter Share on LinkedIn

 

Abbott's Test To Distinguish Coronavirus And Flu Viruses Gets U.S. Authorization

(Reuters) Mar 5, 2021 - Abbott Laboratories said on Friday the U.S. health regulator has granted emergency use authorization for its molecular test to detect and distinguish the coronavirus and two types of flu viruses with a single test.

read article Share on Facebook Share on Twitter Share on LinkedIn

 

FDA To Review Sanofi’s Dupixent In Children With Uncontrolled Asthma

(PharmaTimes [UK]) Mar 5, 2021 - The US Food and Drug Administration (FDA) will review Sanofi’s Dupixent as an add-on treatment for children aged six to 11 years with uncontrolled moderate-to-severe asthma.

read article Share on Facebook Share on Twitter Share on LinkedIn

 

 

 
 
 
© Caribou Publishing. All rights reserved.
3001 Bridgeway, Suite #K124, Sausalito, CA 94965
Unsubscribe  |  Contact Us  | Edit Profile